Compugen (CGEN) Competitors $1.42 -0.03 (-1.72%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEN vs. MBX, ATYR, SLDB, AUTL, PRME, ERAS, ETON, CGEM, TNXP, and ITOSShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include MBX Biosciences (MBX), aTyr Pharma (ATYR), Solid Biosciences (SLDB), Autolus Therapeutics (AUTL), Prime Medicine (PRME), Erasca (ERAS), Eton Pharmaceuticals (ETON), Cullinan Therapeutics (CGEM), Tonix Pharmaceuticals (TNXP), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Compugen vs. Its Competitors MBX Biosciences aTyr Pharma Solid Biosciences Autolus Therapeutics Prime Medicine Erasca Eton Pharmaceuticals Cullinan Therapeutics Tonix Pharmaceuticals iTeos Therapeutics MBX Biosciences (NYSE:MBX) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability. Is MBX or CGEN more profitable? MBX Biosciences has a net margin of 0.00% compared to Compugen's net margin of -87.45%. MBX Biosciences' return on equity of 0.00% beat Compugen's return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A Compugen -87.45%-34.77%-16.82% Which has better valuation and earnings, MBX or CGEN? MBX Biosciences has higher earnings, but lower revenue than Compugen. Compugen is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/A-$4.54-3.08Compugen$27.86M4.56-$14.23M-$0.22-6.48 Do analysts recommend MBX or CGEN? MBX Biosciences presently has a consensus price target of $37.63, indicating a potential upside of 168.65%. Compugen has a consensus price target of $4.00, indicating a potential upside of 180.70%. Given Compugen's higher possible upside, analysts clearly believe Compugen is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer MBX or CGEN? In the previous week, MBX Biosciences had 2 more articles in the media than Compugen. MarketBeat recorded 3 mentions for MBX Biosciences and 1 mentions for Compugen. Compugen's average media sentiment score of 1.67 beat MBX Biosciences' score of 0.00 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders & institutionals hold more shares of MBX or CGEN? 12.2% of Compugen shares are held by institutional investors. 52.2% of MBX Biosciences shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryMBX Biosciences beats Compugen on 7 of the 12 factors compared between the two stocks. Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$127.17M$3.06B$5.76B$9.75BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-6.4821.0030.8325.91Price / Sales4.56392.25469.77121.46Price / CashN/A43.2325.7828.79Price / Book2.309.739.466.03Net Income-$14.23M-$54.08M$3.27B$265.29M7 Day Performance-8.06%3.12%2.37%2.86%1 Month Performance-6.86%4.57%3.88%1.23%1 Year Performance-30.15%10.22%30.52%19.11% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen2.0695 of 5 stars$1.43-1.7%$4.00+180.7%-28.9%$127.17M$27.86M-6.4870Positive NewsMBXMBX Biosciences1.9307 of 5 stars$14.57-1.0%$37.63+158.2%N/A$489.47MN/A-3.2136ATYRaTyr Pharma2.1146 of 5 stars$4.91+0.2%$21.25+332.8%+183.1%$480.14M$230K-6.1453News CoverageAnalyst ForecastSLDBSolid Biosciences3.4099 of 5 stars$6.03-1.3%$15.00+148.8%-38.0%$475.78M$8.09M-2.15100AUTLAutolus Therapeutics2.5636 of 5 stars$1.88+5.6%$9.12+385.1%-56.1%$473.73M$10.12M-2.24330PRMEPrime Medicine2.6942 of 5 stars$3.50-2.0%$8.92+154.8%-19.7%$471.01M$4.96M-1.71234ERASErasca1.9226 of 5 stars$1.53-6.7%$4.29+180.1%-41.8%$465.22MN/A-3.40120News CoverageAnalyst DowngradeETONEton Pharmaceuticals2.1469 of 5 stars$16.37-3.9%$29.67+81.2%+281.1%$456.97M$39.01M-102.3120Positive NewsCGEMCullinan Therapeutics1.9128 of 5 stars$7.95+3.8%$28.60+259.7%-54.6%$452.51MN/A-2.4630News CoverageAnalyst RevisionTNXPTonix Pharmaceuticals2.9848 of 5 stars$40.07-22.0%$70.00+74.7%+11.7%$450.13M$10.09M-1.0250High Trading VolumeITOSiTeos Therapeutics2.6874 of 5 stars$10.11flat$15.50+53.3%-41.7%$446.92M$35M-2.1690 Related Companies and Tools Related Companies MBX Biosciences Alternatives aTyr Pharma Alternatives Solid Biosciences Alternatives Autolus Therapeutics Alternatives Prime Medicine Alternatives Erasca Alternatives Eton Pharmaceuticals Alternatives Cullinan Therapeutics Alternatives Tonix Pharmaceuticals Alternatives iTeos Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEN) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access